Conference
SAT0348 The Economic Value of Tofacitinib 5 Mg Bid in the Treatment of Moderate to Severe Rheumatoid Arthritis: A Canadian Analysis
Abstract
Background As new medications enter the market for rheumatoid arthritis (RA), economic evaluations of medications provide critical information for assessing cost-effectiveness. Objectives To estimate incremental cost per quality-adjusted life-year (QALY) of tofacitinib 5 mg BID, a new treatment for moderate to severe RA after inadequate response to methotrexate (MTX), compared with the available/recommended treatment strategies as of 2014 using …
Authors
Woolcott JC; Blackhouse G; Claxton L; Wallenstein G; Tran T; Goeree R; Taylor M; Moynagh D; Singh A
Volume
74
Publisher
Elsevier
Publication Date
June 2015
DOI
10.1136/annrheumdis-2015-eular.4246
Conference proceedings
Annals of the Rheumatic Diseases
ISSN
0003-4967